June 2003
GP: General Practitioner;6/2/2003, p60
This article introduces several medical products as of June 2, 2003. Pfizer Inc. has launched a dose titration pack for Neurontin to simplify the process of dose titration in patients with neuropathic pain. The pack contains all the capsules and tablets required for the first 15 days of treatment. Active ingredient is gabapentin. Amdipharm has launched Anzemet for the management of nausea and vomiting in patients receiving cancer chemotherapy, and for the prevention of post-operative nausea and vomiting.


Related Articles

  • Scans.  // AHA News;10/29/2001, Vol. 37 Issue 43, p2 

    Presents news briefs on the health care industry in the United States as of October 2001. Participation of the Drug Enforcement Administration in a call for a balanced policy governing the use and abuse of prescription pain medications; Mobilization of Pfizer's relevant resources to combat...

  • One drug eases fibromyalgia….  // Cortlandt Forum;Jun2007, Vol. 20 Issue 6, p16 

    The article reports on the discovery of pregabalin as an effective treatment for fibromyalgia in the U.S. It relieves pain and improves quality of life of fibromyalgia patients. It is stated that drugs from Pfizer Inc. are indicated for diabetic neuropathic pain and postherpetic neuralgia....

  • ICAGEN/PFIZER INITIATE STUDY FOR PAIN/RELATED DISORDERS.  // Biotech Business;Sep2010, Vol. 23 Issue 9, p1 

    The article discusses a study conducted by Icagen, Inc. and Pfizer on its sodium channel program for pain and related disorders. This study was initiated in order to help in the selection of compounds for further clinical development. It has pinpointed novel, potent and selective blockers of the...

  • Pfizer's novel NGF pain drug is potential game changer.  // PharmaWatch: Monthly Review;Mar2010, Vol. 9 Issue 3, p13 

    The article presents the Datamonitor Ltd.'s analysis of Pfizer Inc.'s market for its novel monoclonal antibody (mAb) nerve growth factor (NGF) pain drug tanezumab in the U.S. Datamonitor predicts that Pfizer's new drug can take advantage of a potentially lucrative market for pain therapy....

  • SECTION 16 PAIN & PYREXIA.  // Physician Assistants' Prescribing Reference;Fall2009, Vol. 16 Issue 3, p230 

    The article offers information on the prescribed drugs for treating pain and pyrexia. It highlights treatments for minor aches and pain, trigeminal or glossopharyngeal neuralgia, and diabetic peripheral neuropathic pain which include, Celebrex from Pfizer Inc., Cataflam from Novartis AG, and...

  • PAIN & PYREXIA.  // Nurse Practitioners Prescribing Reference;Spring2010, Vol. 17 Issue 1, p244 

    The article presents several medicines in the U.S. used to treat different types of pain and pyrexia, including nonnarcotic/narcotic analgesics, fibromyalgia and migraine, along with its indications, precautions and adverse reactions. The medicines include Advil from Wyeth Consumer Healthcare...

  • Chapter 15: PAIN MANAGEMENT: 15D: Nonnarcotic analgesics.  // Monthly Prescribing Reference;Aug2014, Vol. 30 Issue 8, p233 

    The article offers brief information on several nonnarcotic analgesics for pain management including the Advil from the company Pfizer Consumer Healthcare, the Cataflam from the company Novartis and the Nalfon from the company Pedinol.

  • Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Campbell, Fiona A; Tramer, Martin R; Carroll, Dawn; Reynolds, D John M; Moore, R Andrew; McQuay, Henry J // BMJ: British Medical Journal (International Edition);7/7/2001, Vol. 323 Issue 7303, Special section p1 

    Conclusion: Cannabinoids are no more effective than codeine in controlling pain and have depressant effects on the central nervous system that limit their use. Their widespread introduction into clinical practice for pain management is therefore undesirable. In acute postoperative pain they...

  • Duloxetine delivers in diabetic peripheral neuropathic pain.  // PharmacoEconomics & Outcomes News;4/16/2011, Issue 626, p6 

    The article discusses the findings of U.S. researchers confirming the lower healthcare costs and higher medication adherence related to the use of duloxetine by patients suffering from diabetic peripheral neuropathic pain.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics